# Navigating the future for HR+/HER2– metastatic breast cancer

Saturday 8 October 2016, 13.00–14.30

Stockholm Auditorium, Bella Center
Copenhagen, Denmark

Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium '**Navigating the future for HR+/HER2– metastatic breast cancer**'. The symposium will be held on Saturday 8 October 2016 at 13.00–14.30, during the ESMO 2016 Congress.

A significant unmet need still exists in treating patients with HR+/HER2– breast cancer, to extend time to progression and maintain quality of life. This year, we have already observed an explosion of data for the CDK4/6 inhibitors, in addition to expanding our knowledge of targeted therapies in the real world.

During our symposium, a distinguished international faculty will review the latest clinical trial evidence for the CDK4/6 inhibitors, to include experiences from the clinic and case-based discussion. Another key focus will be exploring how biomarkers may impact patient selection and the future treatment landscape.

I look forward to welcoming you to Copenhagen and I hope you will join us for what promises to be an engaging and highly educational meeting.

Best regards,

Stephen Johnston, Chair
Professor of Breast Cancer Medicine and Consultant Medical Oncologist
The Royal Marsden and The Institute of Cancer Research, London, UK

Programme

Chair: Stephen Johnston (UK)

Time	Session	Speaker
13.00–13.10	**The journey so far: HR+/HER2– mBC in 2016**	Stephen Johnston (UK)
13.10–13.30	**New directions: CDK4/6 inhibitors in the management of HR+/HER2– mBC**	Nicholas Turner (UK)
13.30–13.50	**Scan the horizon: How will biomarkers shape the landscape?**	Fabrice André (France)
13.50–14.10	**Optimal management of CDK4/6 inhibitors: Learning from experience**	Hope S. Rugo (USA)
14.10–14.25	**Panel discussion**	All faculty
14.25–14.30	**Closing remarks**	Stephen Johnston (UK)

Pfizer *Oncology*
www.pfizer.com